Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1465-993X
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Mutations in the MET tyrosine kinase domain and resistance to tyrosine kinase inhibitors in non-small-cell lung cancer ; volume:24 ; number:1 ; day:25 ; month:1 ; year:2023 ; pages:1-10 ; date:12.2023
Respiratory research ; 24, Heft 1 (25.1.2023), 1-10, 12.2023
- Urheber
-
Yao, Yu
Yang, Huaping
Zhu, Bo
Wang, Song
Pang, Jiaohui
Wu, Xiaoying
Xu, Yang
Zhang, Junli
Zhang, Jinfeng
Ou, Qiuxiang
Tian, Hui
Zhao, Zheng
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12931-023-02329-1
- URN
-
urn:nbn:de:101:1-2023040309403057204695
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:58 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Yao, Yu
- Yang, Huaping
- Zhu, Bo
- Wang, Song
- Pang, Jiaohui
- Wu, Xiaoying
- Xu, Yang
- Zhang, Junli
- Zhang, Jinfeng
- Ou, Qiuxiang
- Tian, Hui
- Zhao, Zheng
- SpringerLink (Online service)
Ähnliche Objekte (12)
RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer
Editorial: Targeting bruton tyrosine kinase
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
Targeting tumour microenvironment by tyrosine kinase inhibitor
Bcr-Abl tyrosine kinase inhibitors- current status
Auto-thiophosphorylation activity of Src tyrosine kinase
Second-generation inhibitors of Bruton tyrosine kinase
VEGFR1-tyrosine kinase signaling in pulmonary fibrosis
Pay structure and firm technological innovation: comparative research based on three pay gaps
On the periodic boundary value problems for fractional nonautonomous differential equations with non-instantaneous impulses
RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer
Editorial: Targeting bruton tyrosine kinase
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
Targeting tumour microenvironment by tyrosine kinase inhibitor
Bcr-Abl tyrosine kinase inhibitors- current status
Auto-thiophosphorylation activity of Src tyrosine kinase
Second-generation inhibitors of Bruton tyrosine kinase
VEGFR1-tyrosine kinase signaling in pulmonary fibrosis
Pay structure and firm technological innovation: comparative research based on three pay gaps
On the periodic boundary value problems for fractional nonautonomous differential equations with non-instantaneous impulses
RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer
Editorial: Targeting bruton tyrosine kinase
Subsequent chemotherapy reverses acquired tyrosine kinase inhibitor resistance and restores response to tyrosine kinase inhibitor in advanced non-small-cell lung cancer
Protein tyrosine kinase 2b inhibition reverts niche-associated resistance to tyrosine kinase inhibitors in AML
Newer Tyrosine Kinase Inhibitors for CML
Targeting tumour microenvironment by tyrosine kinase inhibitor
Bcr-Abl tyrosine kinase inhibitors- current status
Auto-thiophosphorylation activity of Src tyrosine kinase
Second-generation inhibitors of Bruton tyrosine kinase
VEGFR1-tyrosine kinase signaling in pulmonary fibrosis
Pay structure and firm technological innovation: comparative research based on three pay gaps